At its second meeting, Panama’s National System of Reference Prices for Medicines (SINPREM) approved its operating statute. The Ministry of Health and the Social Security Fund agreed to bring their medicine lists with updated reference prices to the next session, set for late January, ahead of state tenders from February.

DRUG PRICING · PUBLIC PROCUREMENT · NOVEMBER 14, 2026 · PANAMA
Panama’s National System of Reference Prices for Medicines (Sistema Nacional de Precios de Referencia de Medicamentos, SINPREM) approved its operating statute at its second meeting, and the Ministry of Health (Ministerio de Salud, Minsa) and the Social Security Fund (Caja de Seguro Social, CSS) agreed to present their lists of medicines with updated reference prices at the next session, the CSS said on November 9. That session is scheduled for late January, and the aim is to have the information before the state’s tender procedures, which are expected to begin in February.
SINPREM, created by Law 419 of 2024, pools the drug needs of Minsa and the CSS and turns negotiated reference prices into maximum prices for public purchases. It was installed on October 26, when approval of the statute was left for a later meeting, as HealthSignals reported.
Late January
Date of SINPREM’s next session, when Minsa and the CSS are to present consolidated medicine lists with updated reference prices, ahead of state tenders starting in February, per the CSS.
What was agreed
Marcos Young, the CSS national executive director of health services and benefits, said the lists will be shared with the Ministry of Economy and Finance, the Ministry of Commerce and Industries and the Ministry of Foreign Affairs. Consolidating the data will allow the institutions to assess joint purchasing mechanisms and set price parameters for institutional purchases, the CSS said.
“This reference price system will set a price ceiling, so that we hope the procurement processes and access to medicines for all Panamanians will be agile,” Young said, according to the CSS. (Quote translated from Spanish by HealthSignals.)
The first stage covers the public system only. In parallel, the CSS said, work is under way with the Consumer Protection and Competition Authority (Autoridad de Protección al Consumidor y Defensa de la Competencia, Acodeco) to find price references for the private market; no date was given. The system also aims to address differences in medicine costs between regions, which Young said can be considerable in hard-to-reach areas, where distribution and logistics affect prices.
The CSS release does not state the date of the second meeting, and neither the medicine list nor any reference price has been published.
Budget and supply context
The CSS had budgeted US$323 million for medicines in 2026 and US$230.3 million for 2027, according to Istmo Hoy. In the same report, Enma Pinzón, president of the National Federation of Associations of Patients with Critical, Chronic and Degenerative Diseases (Fenaeccd), said methotrexate, irbesartan and dapagliflozin were in short supply, and that no tender procedures for medicines had been held in 2026, with contracts extended instead. HealthSignals has not independently verified those claims, and the CSS release does not address them.
What to Watch
- Whether Minsa and the CSS bring consolidated lists and reference prices to the late-January session
- Whether the first 2027 Minsa and CSS tender notices from February carry SINPREM ceilings
- Any timeline from Acodeco on private-market price references
Sources: CSS: MINSA y la CSS avanza en la definición de precios de referencia de medicamentos (November 9, 2026) · Minsa: Minsa instala el SINPREM para negociar mejores precios en la compra de medicamentos · Istmo Hoy: CSS y Minsa afinan precios de referencia para comprar medicamentos · Panamá América: Minsa y CSS alistan listas de precios de referencia de medicamentos
Related coverage
THE HEALTHSIGNALS BRIEF
A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.
Built for pharma, market-access, regulatory, policy and investor teams, with the main findings of our gated reports included.







